MSB
Click for more information
2.17% $1.13 mesoblast limited

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-319

  1. dave sss
    12,336 Posts.
    lightbulb Created with Sketch. 180
    clock Created with Sketch.
    24/04/20
    18:20
    Post #: 44241704

    Stem cell drug shows promise for ventilator-dependent COVID-19 patients

    SYDNEY, April 24 (Xinhua) -- An Australian drug manufacturer has claimed success treating COVID-19 patients who were dependent on ventilators, revealing that seven out of 12 seriously ill patients were discharged from hospital after receiving an experimental stem cell product.

    The study involved 12 ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) and was conducted at New York City's Mt Sinai Hospital in the United States - Aussie company, Mesoblast said in a statement to the Australian Securities Exchange (ASX) on Friday.

    According to the statement, nine out of the 12 subjects successfully came off ventilator support, a median of 10 days after being treated with two intravenous infusions of Mesoblast's allogeneic mesenchymal stem cell product candidate named remestemcel-L.

    In comparison, it claimed that ventilator-dependent COVID-19 patients at a second major referral hospital network in New York City recorded only a 12 percent survival rate during the same period.

    However, it is unclear whether the stem cell product was the sole cause of their recovery because the patients received a variety of other experimental agents prior to remestemcel-L.

    Mesoblast Chief Executive Dr. Silviu Itescu said the results showed the drug's ability to prevent an inflammatory response called a cytokine storm, which is an overreaction by the immune system to COVID-19 and has caused many deaths among patients.

    "The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of remestemcel-L as an anti-inflammatory agent in cytokine release syndromes associated with high mortality, including acute graft versus host disease and COVID-19 ARDS," Itescu said.

    "We intend to rapidly complete the randomized, placebo-controlled Phase 2/3 trial in COVID-19 ARDS patients to rigorously confirm that remestemcel-L improves survival in these critically ill patients." Enditem

    http://www.xinhuanet.com/english/2020-04/24/c_139004793.htm
    MSB Price at posting: $2.73 Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 14  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

FMG Quarterly & half yearly reports: Drives Newmont up, Ampol flat, while Fortescue plunges 2.6%
right-arrow Created with Sketch.
NEWS Capital raisings wrap: Brainchip, Ovanti, Lake and VHM
right-arrow Created with Sketch.
TRP Tissue Repairs soars nearly 32% on TGA approval for wound healing gel
right-arrow Created with Sketch.
NEWS Nine staff strike as Paris Olympic coverage begins
right-arrow Created with Sketch.
PEC Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil
right-arrow Created with Sketch.
NVA Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter
right-arrow Created with Sketch.
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13 		Change
-0.025(2.17%) 		Mkt cap ! $1.284B
Open High Low Value Volume
$1.15 $1.16 $1.11 $7.363M 6.488M

Buyers (Bids)

No. Vol. Price($)
5 94863 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.13 5000 2
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.